FLGT - CIK 0001674930
The table below shows Fulgent Genetics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $7.10M | -$4.43M | $7.27M | -$7.91M | $188.41M | $233.18M |
| Capital expenditure | $5.20M | $4.72M | $4.06M | $2.03M | $5.36M | $11.49M |
| Investing cash flow | $10.94M | $27.73M | -$47.19M | -$4.35M | $688.00K | -$216.49M |
| Dividends paid | - | - | - | - | - |
Fulgent Genetics, Inc. reported operating cash flow of -$101.64M for fiscal year 2025. That is down 582.6% from $21.06M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $4.41M (FY 2016) to -$101.64M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $40.08M | $8.68M | $225.00K | - | - | $513.00K |
| Financing cash flow | -$44.83M | -$11.17M | -$2.81M | -$1.10M | -$934.00K | $47.35M |